Hasselbalch HC - Search Results

1

Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?

Hasselbalch HC. Hasselbalch HC. Leuk Res. 2013 Feb;37(2):214-20. doi: 10.1016/j.leukres.2012.10.020. Epub 2012 Nov 20. Leuk Res. 2013. PMID: 23174192 Review.

2

Statins in the treatment of polycythaemia vera and allied disorders: an antithrombotic and cytoreductive potential?

Hasselbalch HC, Riley CH. Hasselbalch HC, et al. Leuk Res. 2006 Oct;30(10):1217-25. doi: 10.1016/j.leukres.2005.12.018. Epub 2006 Feb 17. Leuk Res. 2006. PMID: 16483650 Review.

3

The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.

Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC. Larsen TS, et al. Among authors: hasselbalch hc. Eur J Haematol. 2007 Dec;79(6):508-15. doi: 10.1111/j.1600-0609.2007.00960.x. Epub 2007 Oct 23. Eur J Haematol. 2007. PMID: 17961178

4

Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera.

Larsen TS, Bjerrum OW, Pallisgaard N, Andersen MT, Møller MB, Hasselbalch HC. Larsen TS, et al. Among authors: hasselbalch hc. Ann Hematol. 2008 Oct;87(10):847-50. doi: 10.1007/s00277-008-0498-4. Epub 2008 May 15. Ann Hematol. 2008. PMID: 18481066

5

Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated hematological cancer. Time to change our therapeutic attitude with early upfront treatment?

Hasselbalch HC. Hasselbalch HC. Leuk Res. 2009 Jan;33(1):11-8. doi: 10.1016/j.leukres.2008.06.002. Epub 2008 Jul 15. Leuk Res. 2009. PMID: 18632152 Review.

6

Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectives.

Hasselbalch HC, Larsen TS, Riley CH, Jensen MK, Kiladjian JJ. Hasselbalch HC, et al. Curr Drug Targets. 2011 Mar 1;12(3):392-419. doi: 10.2174/138945011794815275. Curr Drug Targets. 2011. PMID: 21143149 Review.

7

High expression of carcinoembryonic antigen-related cell adhesion molecule (CEACAM) 6 and 8 in primary myelofibrosis.

Hasselbalch HC, Skov V, Larsen TS, Thomassen M, Riley CH, Jensen MK, Bjerrum OW, Kruse TA. Hasselbalch HC, et al. Leuk Res. 2011 Oct;35(10):1330-4. doi: 10.1016/j.leukres.2011.03.013. Epub 2011 Apr 5. Leuk Res. 2011. PMID: 21470677

8

The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis.

Risum M, Madelung A, Bondo H, Bzorek M, Kristensen MH, Stamp IM, Hasselbalch HC. Risum M, et al. Among authors: hasselbalch hc. APMIS. 2011 Aug;119(8):498-504. doi: 10.1111/j.1600-0463.2011.02754.x. Epub 2011 Apr 17. APMIS. 2011. PMID: 21749449

9

Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms.

Skov V, Larsen TS, Thomassen M, Riley CH, Jensen MK, Bjerrum OW, Kruse TA, Hasselbalch HC. Skov V, et al. Among authors: hasselbalch hc. Leuk Lymphoma. 2012 Jan;53(1):123-9. doi: 10.3109/10428194.2011.597905. Epub 2011 Aug 1. Leuk Lymphoma. 2012. PMID: 21806350

10

A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms.

Hasselbalch HC. Hasselbalch HC. Expert Rev Hematol. 2011 Dec;4(6):637-55. doi: 10.1586/ehm.11.63. Expert Rev Hematol. 2011. PMID: 22077528 Review.

11

Lack of somatic mutations in the catalytic domains of CREBBP and EP300 genes implies a role for histone deacetylase inhibition in myeloproliferative neoplasms.

Andersen CL, Hasselbalch H, Grønbæk K. Andersen CL, et al. Leuk Res. 2012 Apr;36(4):485-7. doi: 10.1016/j.leukres.2011.11.018. Epub 2011 Dec 15. Leuk Res. 2012. PMID: 22177454

12

Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?

Hasselbalch HC. Hasselbalch HC. Blood. 2012 Apr 5;119(14):3219-25. doi: 10.1182/blood-2011-11-394775. Epub 2012 Feb 7. Blood. 2012. PMID: 22318201 Free article.

13

Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis.

Skov V, Thomassen M, Riley CH, Jensen MK, Bjerrum OW, Kruse TA, Hasselbalch HC, Larsen TS. Skov V, et al. Among authors: hasselbalch hc. Exp Hematol. 2012 Sep;40(9):771-780.e19. doi: 10.1016/j.exphem.2012.05.011. Epub 2012 Jun 1. Exp Hematol. 2012. PMID: 22659388 Free article.

14

Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: identification of deregulated genes of significance for inflammation and immune surveillance.

Skov V, Larsen TS, Thomassen M, Riley CH, Jensen MK, Bjerrum OW, Kruse TA, Hasselbalch HC. Skov V, et al. Among authors: hasselbalch hc. Leuk Res. 2012 Nov;36(11):1387-92. doi: 10.1016/j.leukres.2012.07.009. Epub 2012 Aug 9. Leuk Res. 2012. PMID: 22877729

15

Inheritance of the chronic myeloproliferative neoplasms. A systematic review.

Ranjan A, Penninga E, Jelsig AM, Hasselbalch HC, Bjerrum OW. Ranjan A, et al. Among authors: hasselbalch hc. Clin Genet. 2013 Feb;83(2):99-107. doi: 10.1111/cge.12044. Epub 2012 Nov 20. Clin Genet. 2013. PMID: 23094849

16

Whole blood transcriptional profiling reveals significant down-regulation of human leukocyte antigen class I and II genes in essential thrombocythemia, polycythemia vera and myelofibrosis.

Skov V, Riley CH, Thomassen M, Larsen TS, Jensen MK, Bjerrum OW, Kruse TA, Hasselbalch HC. Skov V, et al. Among authors: hasselbalch hc. Leuk Lymphoma. 2013 Oct;54(10):2269-73. doi: 10.3109/10428194.2013.764417. Epub 2013 May 15. Leuk Lymphoma. 2013. PMID: 23302045

17

Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis.

Silver RT, Kiladjian JJ, Hasselbalch HC. Silver RT, et al. Among authors: hasselbalch hc. Expert Rev Hematol. 2013 Feb;6(1):49-58. doi: 10.1586/ehm.12.69. Expert Rev Hematol. 2013. PMID: 23373780

18

The role of cytokines in the initiation and progression of myelofibrosis.

Hasselbalch HC. Hasselbalch HC. Cytokine Growth Factor Rev. 2013 Apr;24(2):133-45. doi: 10.1016/j.cytogfr.2013.01.004. Epub 2013 Feb 13. Cytokine Growth Factor Rev. 2013. PMID: 23415024 Review.

19

Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha.

Stauffer Larsen T, Iversen KF, Hansen E, Mathiasen AB, Marcher C, Frederiksen M, Larsen H, Helleberg I, Riley CH, Bjerrum OW, Rønnov-Jessen D, Møller MB, de Stricker K, Vestergaard H, Hasselbalch HC. Stauffer Larsen T, et al. Among authors: hasselbalch hc. Leuk Res. 2013 Sep;37(9):1041-5. doi: 10.1016/j.leukres.2013.06.012. Epub 2013 Jul 1. Leuk Res. 2013. PMID: 23827351

20

A role of NF-E2 in chronic inflammation and clonal evolution in essential thrombocythemia, polycythemia vera and myelofibrosis?

Hasselbalch HC. Hasselbalch HC. Leuk Res. 2014 Feb;38(2):263-6. doi: 10.1016/j.leukres.2013.07.002. Epub 2013 Aug 9. Leuk Res. 2014. PMID: 23932394

21

Somatic mutations of the CREBBP and EP300 genes affect response to histone deacetylase inhibition in malignant DLBCL clones.

Andersen CL, Asmar F, Klausen T, Hasselbalch H, Grønbæk K. Andersen CL, et al. Leuk Res Rep. 2012 Dec 8;2(1):1-3. doi: 10.1016/j.lrr.2012.10.002. eCollection 2012. Leuk Res Rep. 2012. PMID: 24371765 Free PMC article.

22

Myeloproliferative neoplasms in five multiple sclerosis patients.

Thorsteinsdottir S, Bjerrum OW, Hasselbalch HC. Thorsteinsdottir S, et al. Among authors: hasselbalch hc. Leuk Res Rep. 2013 Jul 31;2(2):61-3. doi: 10.1016/j.lrr.2013.06.004. eCollection 2013. Leuk Res Rep. 2013. PMID: 24371783 Free PMC article.

23

Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms.

Hasselbalch HC. Hasselbalch HC. Expert Rev Hematol. 2014 Apr;7(2):203-16. doi: 10.1586/17474086.2013.876356. Epub 2014 Feb 13. Expert Rev Hematol. 2014. PMID: 24524202

24

Chronic kidney disease in patients with the Philadelphia-negative chronic myeloproliferative neoplasms.

Christensen AS, Møller JB, Hasselbalch HC. Christensen AS, et al. Among authors: hasselbalch hc. Leuk Res. 2014 Apr;38(4):490-5. doi: 10.1016/j.leukres.2014.01.014. Epub 2014 Feb 4. Leuk Res. 2014. PMID: 24630365

25

Circulating YKL-40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory state.

Bjørn ME, Andersen CL, Jensen MK, Hasselbalch HC. Bjørn ME, et al. Among authors: hasselbalch hc. Eur J Haematol. 2014 Sep;93(3):224-8. doi: 10.1111/ejh.12332. Epub 2014 Apr 25. Eur J Haematol. 2014. PMID: 24689875

26

Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat.

Andersen CL, Bjørn ME, McMullin MF, Harrison C, Samuelsson J, Ejerblad E, Zweegman S, Fernandes S, Bareford D, Knapper S, Löfvenberg E, Linder O, Andreasson B, Ahlstrand E, Jensen MK, Bjerrum OW, Vestergaard H, Larsen H, Klausen TW, Mourits-Andersen T, Skov V, Thomassen M, Kruse T, Grønbæk K, Hasselbalch HC. Andersen CL, et al. Among authors: hasselbalch hc. Leuk Res. 2014 Jul;38(7):816-21. doi: 10.1016/j.leukres.2014.04.002. Epub 2014 Apr 14. Leuk Res. 2014. PMID: 24836761 Clinical Trial.

27

The platelet-cancer loop in myeloproliferative cancer. Is thrombocythemia an enhancer of cancer invasiveness and metastasis in essential thrombocythemia, polycythemia vera and myelofibrosis?

Hasselbalch HC. Hasselbalch HC. Leuk Res. 2014 Oct;38(10):1230-6. doi: 10.1016/j.leukres.2014.07.006. Epub 2014 Jul 22. Leuk Res. 2014. PMID: 25149709

28

Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera.

Bjørn ME, de Stricker K, Kjær L, Ellemann K, Hasselbalch HC. Bjørn ME, et al. Among authors: hasselbalch hc. Leuk Res Rep. 2014 Aug 1;3(2):73-5. doi: 10.1016/j.lrr.2014.05.003. eCollection 2014. Leuk Res Rep. 2014. PMID: 25379406 Free PMC article.

29

Whole blood transcriptional profiling reveals deregulation of oxidative and antioxidative defence genes in myelofibrosis and related neoplasms. Potential implications of downregulation of Nrf2 for genomic instability and disease progression.

Hasselbalch HC, Thomassen M, Riley CH, Kjær L, Larsen TS, Jensen MK, Bjerrum OW, Kruse TA, Skov V. Hasselbalch HC, et al. PLoS One. 2014 Nov 14;9(11):e112786. doi: 10.1371/journal.pone.0112786. eCollection 2014. PLoS One. 2014. PMID: 25397683 Free PMC article.

30

Perspectives on the increased risk of second cancer in patients with essential thrombocythemia, polycythemia vera and myelofibrosis.

Hasselbalch HC. Hasselbalch HC. Eur J Haematol. 2015 Feb;94(2):96-8. doi: 10.1111/ejh.12437. Eur J Haematol. 2015. PMID: 25689636 No abstract available.

31

Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients.

Bjørn ME, Holmström MO, Hasselbalch HC. Bjørn ME, et al. Among authors: hasselbalch hc. Leuk Lymphoma. 2016;57(1):125-8. doi: 10.3109/10428194.2015.1046867. Epub 2015 Sep 23. Leuk Lymphoma. 2016. PMID: 25936872

32

Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera.

Utke Rank C, Weis Bjerrum O, Larsen TS, Kjær L, de Stricker K, Riley CH, Hasselbalch HC. Utke Rank C, et al. Among authors: hasselbalch hc. Leuk Lymphoma. 2016 Feb;57(2):348-354. doi: 10.3109/10428194.2015.1049171. Epub 2015 Jun 18. Leuk Lymphoma. 2016. PMID: 25956046

33

[Status and perspectives on chronic myeloproliferative neoplasm treatment].

Ocias LF, Holmström MO, Riley CH, Andersen CL, Rønnov-Jessen D, Starklint J, Frederiksen M, Steffensen MS, Bjerrum OW, Farmer S, Mourits-Andersen T, Hasselbalch HC, Larsen TS. Ocias LF, et al. Among authors: hasselbalch hc. Ugeskr Laeger. 2015 May 4;177(19):V12140652. Ugeskr Laeger. 2015. PMID: 25967090 Free article. Review. Danish.

34

Interferon in polycythemia vera and related neoplasms. Can it become the treatment of choice without a randomized trial?

Hasselbalch HC, Silver RT. Hasselbalch HC, et al. Expert Rev Hematol. 2015 Aug;8(4):439-45. doi: 10.1586/17474086.2015.1045409. Epub 2015 May 21. Expert Rev Hematol. 2015. PMID: 25996953

35

Corrigendum to "Combination therapy with interferon and JAK1-2 inhibitor is feasible. Proof of concept with rapid reduction in JAK2V617F-allele burden in Polycythemia Vera" [Leuk. Res. Rep. 3 (2) (2014) 73-75].

Bjørn ME, de Stricker K, Kjær L, Ellemann K, Hasselbalch HC. Bjørn ME, et al. Among authors: hasselbalch hc. Leuk Res Rep. 2015 May 15;4(1):31. doi: 10.1016/j.lrr.2015.04.003. eCollection 2015. Leuk Res Rep. 2015. PMID: 26101742 Free PMC article.

36

Smoking as a contributing factor for development of polycythemia vera and related neoplasms.

Hasselbalch HC. Hasselbalch HC. Leuk Res. 2015 Sep 9:S0145-2126(15)30373-8. doi: 10.1016/j.leukres.2015.09.002. Online ahead of print. Leuk Res. 2015. PMID: 26463040 Review.

37

The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms.

Bjørn ME, Hasselbalch HC. Bjørn ME, et al. Among authors: hasselbalch hc. Mediators Inflamm. 2015;2015:648090. doi: 10.1155/2015/648090. Epub 2015 Oct 11. Mediators Inflamm. 2015. PMID: 26538833 Free PMC article. Review.

38

MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives.

Hasselbalch HC, Bjørn ME. Hasselbalch HC, et al. Mediators Inflamm. 2015;2015:102476. doi: 10.1155/2015/102476. Epub 2015 Oct 28. Mediators Inflamm. 2015. PMID: 26604428 Free PMC article. Review.

39

Antecedent cardiovascular disease and autoimmunity in Philadelphia-negative chronic myeloproliferative neoplasms.

Sørensen AL, Hasselbalch HC. Sørensen AL, et al. Among authors: hasselbalch hc. Leuk Res. 2016 Feb;41:27-35. doi: 10.1016/j.leukres.2015.11.017. Epub 2015 Dec 2. Leuk Res. 2016. PMID: 26718091

40

Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both.

Koschmieder S, Mughal TI, Hasselbalch HC, Barosi G, Valent P, Kiladjian JJ, Jeryczynski G, Gisslinger H, Jutzi JS, Pahl HL, Hehlmann R, Maria Vannucchi A, Cervantes F, Silver RT, Barbui T. Koschmieder S, et al. Among authors: hasselbalch hc. Leukemia. 2016 May;30(5):1018-24. doi: 10.1038/leu.2016.12. Epub 2016 Feb 8. Leukemia. 2016. PMID: 26854026 Review.

41

Chronic inflammation and autoimmunity as risk factors for the development of chronic myelomonocytic leukemia?

Elbæk MV, Sørensen AL, Hasselbalch HC. Elbæk MV, et al. Among authors: hasselbalch hc. Leuk Lymphoma. 2016 Aug;57(8):1793-9. doi: 10.3109/10428194.2016.1143938. Epub 2016 Feb 16. Leuk Lymphoma. 2016. PMID: 26879691

42

Optimal therapy for polycythemia vera and essential thrombocythemia: Preferred use of interferon therapy based on phase 2 trials.

Silver RT, Hasselbalch HC. Silver RT, et al. Among authors: hasselbalch hc. Hematology. 2016 Aug;21(7):387-91. doi: 10.1080/10245332.2015.1111644. Epub 2016 Feb 26. Hematology. 2016. PMID: 26900719 Free article.

43

A remarkable hematological and molecular response pattern in a patient with polycythemia vera during combination therapy with simvastatin and alendronate.

Sørensen AL, Kallenbach K, Hasselbalch HC. Sørensen AL, et al. Among authors: hasselbalch hc. Leuk Res Rep. 2016 Jun 27;6:20-3. doi: 10.1016/j.lrr.2016.06.004. eCollection 2016. Leuk Res Rep. 2016. PMID: 27489765 Free PMC article.

44

The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms.

Holmström MO, Riley CH, Svane IM, Hasselbalch HC, Andersen MH. Holmström MO, et al. Among authors: hasselbalch hc. Leukemia. 2016 Dec;30(12):2413-2416. doi: 10.1038/leu.2016.233. Epub 2016 Aug 18. Leukemia. 2016. PMID: 27560107 No abstract available.

45

The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms.

Holmström MO, Hjortsø MD, Ahmad SM, Met Ö, Martinenaite E, Riley C, Straten P, Svane IM, Hasselbalch HC, Andersen MH. Holmström MO, et al. Among authors: hasselbalch hc. Leukemia. 2017 Feb;31(2):495-498. doi: 10.1038/leu.2016.290. Epub 2016 Oct 20. Leukemia. 2017. PMID: 27761006 No abstract available.

46

The impact of interferon-alpha2 on HLA genes in patients with polycythemia vera and related neoplasms.

Skov V, Riley CH, Thomassen M, Kjær L, Stauffer Larsen T, Bjerrum OW, Kruse TA, Hasselbalch HC. Skov V, et al. Among authors: hasselbalch hc. Leuk Lymphoma. 2017 Aug;58(8):1914-1921. doi: 10.1080/10428194.2016.1262032. Epub 2016 Dec 2. Leuk Lymphoma. 2017. PMID: 27911124

47

The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy.

Holmström MO, Martinenaite E, Ahmad SM, Met Ö, Friese C, Kjær L, Riley CH, Thor Straten P, Svane IM, Hasselbalch HC, Andersen MH. Holmström MO, et al. Among authors: hasselbalch hc. Leukemia. 2018 Feb;32(2):429-437. doi: 10.1038/leu.2017.214. Epub 2017 Jul 5. Leukemia. 2018. PMID: 28676668

48

Sorted peripheral blood cells identify CALR mutations in B- and T-lymphocytes.

Kjaer L, Holmström MO, Cordua S, Andersen MH, Svane IM, Thomassen M, Kruse TA, Pallisgaard N, Skov V, Hasselbalch HC. Kjaer L, et al. Among authors: hasselbalch hc. Leuk Lymphoma. 2018 Apr;59(4):973-977. doi: 10.1080/10428194.2017.1359743. Epub 2017 Aug 9. Leuk Lymphoma. 2018. PMID: 28792253 No abstract available.

49

Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development.

Andersen M, Sajid Z, Pedersen RK, Gudmand-Hoeyer J, Ellervik C, Skov V, Kjær L, Pallisgaard N, Kruse TA, Thomassen M, Troelsen J, Hasselbalch HC, Ottesen JT. Andersen M, et al. Among authors: hasselbalch hc. PLoS One. 2017 Aug 31;12(8):e0183620. doi: 10.1371/journal.pone.0183620. eCollection 2017. PLoS One. 2017. PMID: 28859112 Free PMC article.

50

Distinguishing myelofibrosis from polycythemia vera and essential thrombocythemia: The utility of enumerating circulating stem cells with aberrant hMICL expression by flow cytometry.

Herborg LL, Nederby L, Hasselbalch HC, Aggerholm A, Roug AS. Herborg LL, et al. Among authors: hasselbalch hc. Int J Lab Hematol. 2018 Jun;40(3):320-325. doi: 10.1111/ijlh.12787. Epub 2018 Feb 10. Int J Lab Hematol. 2018. PMID: 29427319

51

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.

Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R, Reiter A, Cervantes F, Harrison C, Mc Mullin MF, Hasselbalch HC, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G, Kroeger N, Griesshammer M, Birgegard G, Barosi G. Barbui T, et al. Among authors: hasselbalch hc. Leukemia. 2018 May;32(5):1057-1069. doi: 10.1038/s41375-018-0077-1. Epub 2018 Feb 27. Leukemia. 2018. PMID: 29515238 Free PMC article. Review.

52

Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis.

Mikkelsen SU, Kjaer L, Bjørn ME, Knudsen TA, Sørensen AL, Andersen CBL, Bjerrum OW, Brochmann N, Fassi DE, Kruse TA, Larsen TS, Mourits-Andersen HT, Nielsen CH, Pallisgaard N, Thomassen M, Skov V, Hasselbalch HC. Mikkelsen SU, et al. Among authors: hasselbalch hc. Cancer Med. 2018 Aug;7(8):3571-3581. doi: 10.1002/cam4.1619. Epub 2018 Jun 22. Cancer Med. 2018. PMID: 29932310 Free PMC article. Clinical Trial.

53

Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?

Hasselbalch HC, Holmström MO. Hasselbalch HC, et al. Semin Immunopathol. 2019 Jan;41(1):5-19. doi: 10.1007/s00281-018-0700-2. Epub 2018 Sep 10. Semin Immunopathol. 2019. PMID: 30203226 Free PMC article. Review.

54

JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation.

Czech J, Cordua S, Weinbergerova B, Baumeister J, Crepcia A, Han L, Maié T, Costa IG, Denecke B, Maurer A, Schubert C, Feldberg K, Gezer D, Brümmendorf TH, Müller-Newen G, Mayer J, Racil Z, Kubesova B, Knudsen T, Sørensen AL, Holmström M, Kjær L, Skov V, Larsen TS, Hasselbalch HC, Chatain N, Koschmieder S. Czech J, et al. Among authors: hasselbalch hc. Leukemia. 2019 Apr;33(4):995-1010. doi: 10.1038/s41375-018-0295-6. Epub 2018 Nov 23. Leukemia. 2019. PMID: 30470838

55

Ruxolitinib treatment reduces monocytic superoxide radical formation without affecting hydrogen peroxide formation or systemic oxidative nucleoside damage in myelofibrosis.

Bjørn ME, Brimnes MK, Gudbrandsdottir S, Andersen CL, Poulsen HE, Henriksen T, Hasselbalch HC, Nielsen CH. Bjørn ME, et al. Among authors: hasselbalch hc. Leuk Lymphoma. 2019 Oct;60(10):2549-2557. doi: 10.1080/10428194.2019.1579323. Epub 2019 Feb 20. Leuk Lymphoma. 2019. PMID: 30785365

56

Progression of JAK2-mutant polycythemia vera to CALR-mutant myelofibrosis severely impacts on disease phenotype and response to therapy.

Holmström MO, Novotny GW, Petersen J, Aaboe-Jørgensen M, Hasselbalch HC, Andersen MH, Nielsen SL, Fassi DE, Schöllkopf C. Holmström MO, et al. Among authors: hasselbalch hc. Leuk Lymphoma. 2019 Dec;60(13):3296-3299. doi: 10.1080/10428194.2019.1633634. Epub 2019 Jul 1. Leuk Lymphoma. 2019. PMID: 31256699 No abstract available.

57

Time for revival of the red blood cell count and red cell mass in the differential diagnosis between essential thrombocythemia and polycythemia vera?

Hasselbalch HC. Hasselbalch HC. Haematologica. 2019 Nov;104(11):2119-2125. doi: 10.3324/haematol.2019.229039. Haematologica. 2019. PMID: 31666340 Free PMC article. No abstract available.

58

Myeloproliferative blood cancers as a human neuroinflammation model for development of Alzheimer's disease: evidences and perspectives.

Hasselbalch HC, Skov V, Kjær L, Sørensen TL, Ellervik C, Wienecke T. Hasselbalch HC, et al. J Neuroinflammation. 2020 Aug 23;17(1):248. doi: 10.1186/s12974-020-01877-3. J Neuroinflammation. 2020. PMID: 32829706 Free PMC article. Review.

59

Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study.

Sørensen AL, Mikkelsen SU, Knudsen TA, Bjørn ME, Andersen CL, Bjerrum OW, Brochmann N, Patel DA, Gjerdrum LMR, El Fassi D, Kruse TA, Larsen TS, Mourits-Andersen HT, Nielsen CH, Ellervik C, Pallisgaard N, Thomassen M, Kjær L, Skov V, Hasselbalch HC. Sørensen AL, et al. Among authors: hasselbalch hc. Haematologica. 2020 Sep 1;105(9):2262-2272. doi: 10.3324/haematol.2019.235648. Haematologica. 2020. PMID: 33054051 Free PMC article. Clinical Trial.

60

Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b.

Kiladjian JJ, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, Dulicek P, Illes A, Pylypenko H, Sivcheva L, Mayer J, Yablokova V, Krejcy K, Empson V, Hasselbalch HC, Kralovics R, Gisslinger H; PROUD-PV Study Group. Kiladjian JJ, et al. Among authors: hasselbalch hc. Leukemia. 2022 May;36(5):1408-1411. doi: 10.1038/s41375-022-01528-x. Epub 2022 Feb 24. Leukemia. 2022. PMID: 35210530 Free PMC article. No abstract available.

61

Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms.

Skov V, Thomassen M, Kjær L, Ellervik C, Larsen MK, Knudsen TA, Kruse TA, Hasselbalch HC. Skov V, et al. Among authors: hasselbalch hc. PLoS One. 2022 Jun 30;17(6):e0270669. doi: 10.1371/journal.pone.0270669. eCollection 2022. PLoS One. 2022. PMID: 35771847 Free PMC article.

62

A paradigm shift in the treatment of patients with polycythemia vera. The initial early use of recombinant interferon-alpha.

Silver RT, Hasselbalch HC. Silver RT, et al. Among authors: hasselbalch hc. Leukemia. 2026 Apr 8. doi: 10.1038/s41375-026-02882-w. Online ahead of print. Leukemia. 2026. PMID: 41951941 Review.

63

Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.

Michiels JJ, Kutti J, Stark P, Bazzan M, Gugliotta L, Marchioli R, Griesshammer M, van Genderen PJ, Brière J, Kiladjian JJ, Barbui T, Finazzi G, Berlin NI, Pearson TC, Green AC, Fruchtmann SM, Silver RT, Hansmann E, Wehmeier A, Lengfelder E, Landolfi R, Kvasnicka HM, Hasselbalch H, Cervantes F, Thiele J, et al. Michiels JJ, et al. Neth J Med. 1999 Feb;54(2):46-62. doi: 10.1016/s0300-2977(98)00143-0. Neth J Med. 1999. PMID: 10079679 Review.

64

High prevalence of hyperhomocysteinemia due to marginal deficiency of cobalamin or folate in chronic myeloproliferative disorders.

Faurschou M, Nielsen OJ, Jensen MK, Hasselbalch HC. Faurschou M, et al. Among authors: hasselbalch hc. Am J Hematol. 2000 Oct;65(2):136-40. doi: 10.1002/1096-8652(200010)65:2<136::aid-ajh8>3.0.co;2-6. Am J Hematol. 2000. PMID: 10996831 Free article.

65

Elevated soluble urokinase plasminogen activator receptor in plasma from patients with idiopathic myelofibrosis or polycythaemia vera.

Jensen MK, Riisbro R, de Nully Brown P, Brünner N, Hasselbalch HC. Jensen MK, et al. Among authors: hasselbalch hc. Eur J Haematol. 2002 Jul;69(1):43-9. doi: 10.1034/j.1600-0609.2002.01732.x. Eur J Haematol. 2002. PMID: 12270061

66

SU6668 in idiopathic myelofibrosis--a rational therapeutic approach targeting several tyrosine kinases of importance for the myeloproliferation and the development of bone marrow fibrosis and angiogenesis.

Hasselbalch HC. Hasselbalch HC. Med Hypotheses. 2003 Aug;61(2):244-7. doi: 10.1016/s0306-9877(03)00155-5. Med Hypotheses. 2003. PMID: 12888313

67

A der(18)t(9;18)(p13;p11) and a der(9;18)(p10;q10) in polycythemia vera associated with a hyperproliferative phenotype in transformation to postpolycythemic myelofibrosis.

Larsen TS, Hasselbalch HC, Pallisgaard N, Kerndrup GB. Larsen TS, et al. Among authors: hasselbalch hc. Cancer Genet Cytogenet. 2007 Jan 15;172(2):107-12. doi: 10.1016/j.cancergencyto.2006.09.015. Cancer Genet Cytogenet. 2007. PMID: 17213018

68

A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group.

Barosi G, Besses C, Birgegard G, Briere J, Cervantes F, Finazzi G, Gisslinger H, Griesshammer M, Gugliotta L, Harrison C, Hasselbalch H, Lengfelder E, Reilly JT, Michiels JJ, Barbui T. Barosi G, et al. Leukemia. 2007 Feb;21(2):277-80. doi: 10.1038/sj.leu.2404473. Epub 2006 Nov 16. Leukemia. 2007. PMID: 17251900

69

The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders.

Larsen TS, Christensen JH, Hasselbalch HC, Pallisgaard N. Larsen TS, et al. Among authors: hasselbalch hc. Br J Haematol. 2007 Mar;136(5):745-51. doi: 10.1111/j.1365-2141.2007.06497.x. Br J Haematol. 2007. PMID: 17313377

70

Quantitative assessment of the JAK2 V617F allele burden: equivalent levels in peripheral blood and bone marrow.

Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC. Larsen TS, et al. Among authors: hasselbalch hc. Leukemia. 2008 Jan;22(1):194-5. doi: 10.1038/sj.leu.2404861. Epub 2007 Jul 12. Leukemia. 2008. PMID: 17625603 No abstract available.

71

Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission.

Larsen TS, Møller MB, de Stricker K, Nørgaard P, Samuelsson J, Marcher C, Andersen MT, Bjerrum OW, Hasselbalch HC. Larsen TS, et al. Among authors: hasselbalch hc. Hematology. 2009 Dec;14(6):331-4. doi: 10.1179/102453309X12473408860587. Hematology. 2009. PMID: 19941739 Free article.

72

Whole-blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis.

Skov V, Larsen TS, Thomassen M, Riley CH, Jensen MK, Bjerrum OW, Kruse TA, Hasselbalch HC. Skov V, et al. Among authors: hasselbalch hc. Eur J Haematol. 2011 Jul;87(1):54-60. doi: 10.1111/j.1600-0609.2011.01618.x. Eur J Haematol. 2011. PMID: 21447007

73

Increase in circulating CD4⁺CD25⁺Foxp3⁺ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-α.

Riley CH, Jensen MK, Brimnes MK, Hasselbalch HC, Bjerrum OW, Straten PT, Svane IM. Riley CH, et al. Among authors: hasselbalch hc. Blood. 2011 Aug 25;118(8):2170-3. doi: 10.1182/blood-2011-03-340992. Epub 2011 Jun 27. Blood. 2011. PMID: 21708889 Free article.

74

Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study.

Frederiksen H, Farkas DK, Christiansen CF, Hasselbalch HC, Sørensen HT. Frederiksen H, et al. Among authors: hasselbalch hc. Blood. 2011 Dec 15;118(25):6515-20. doi: 10.1182/blood-2011-04-348755. Epub 2011 Oct 28. Blood. 2011. PMID: 22039256 Free article.

75

A highly sensitive quantitative real-time PCR assay for determination of mutant JAK2 exon 12 allele burden.

Kjær L, Westman M, Hasselbalch Riley C, Høgdall E, Weis Bjerrum O, Hasselbalch H. Kjær L, et al. PLoS One. 2012;7(3):e33100. doi: 10.1371/journal.pone.0033100. Epub 2012 Mar 5. PLoS One. 2012. PMID: 22403733 Free PMC article.

76

A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia.

Andersen CL, McMullin MF, Ejerblad E, Zweegman S, Harrison C, Fernandes S, Bareford D, Knapper S, Samuelsson J, Löfvenberg E, Linder O, Andreasson B, Ahlstrand E, Jensen MK, Bjerrum OW, Vestergaard H, Larsen H, Klausen TW, Mourits-Andersen T, Hasselbalch HC. Andersen CL, et al. Among authors: hasselbalch hc. Br J Haematol. 2013 Aug;162(4):498-508. doi: 10.1111/bjh.12416. Epub 2013 Jun 11. Br J Haematol. 2013. PMID: 23758082 Clinical Trial.

77

Transcriptional profiling of whole blood identifies a unique 5-gene signature for myelofibrosis and imminent myelofibrosis transformation.

Hasselbalch HC, Skov V, Stauffer Larsen T, Thomassen M, Hasselbalch Riley C, Jensen MK, Bjerrum OW, Kruse TA. Hasselbalch HC, et al. Among authors: hasselbalch riley c. PLoS One. 2014 Jan 13;9(1):e85567. doi: 10.1371/journal.pone.0085567. eCollection 2014. PLoS One. 2014. PMID: 24454890 Free PMC article.

78

Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α.

Riley CH, Hansen M, Brimnes MK, Hasselbalch HC, Bjerrum OW, Straten PT, Svane IM, Jensen MK. Riley CH, et al. Among authors: hasselbalch hc. Eur J Haematol. 2015 Mar;94(3):227-34. doi: 10.1111/ejh.12420. Epub 2014 Sep 24. Eur J Haematol. 2015. PMID: 25082025

79

[New disease markers within the chronic myeloproliferative neoplasms].

Holmström MO, Ocias LF, Kallenbach K, Kjær L, Kristensen TK, Pallisgaard N, Petersen BL, Skov V, de Stricker K, Larsen TS, Hasselbalch HC. Holmström MO, et al. Among authors: hasselbalch hc. Ugeskr Laeger. 2015 May 4;177(19):V12140653. Ugeskr Laeger. 2015. PMID: 25967091 Free article. Review. Danish.

80

The impact of ruxolitinib treatment on inflammation-mediated comorbidities in myelofibrosis and related neoplasms.

Bjørn ME, Hasselbalch HC. Bjørn ME, et al. Among authors: hasselbalch hc. Clin Case Rep. 2015 Jun;3(6):499-503. doi: 10.1002/ccr3.281. Epub 2015 May 4. Clin Case Rep. 2015. PMID: 26185657 Free PMC article.

81

Smoking and philadelphia-negative chronic myeloproliferative neoplasms.

Lindholm Sørensen A, Hasselbalch HC. Lindholm Sørensen A, et al. Among authors: hasselbalch hc. Eur J Haematol. 2016 Jul;97(1):63-9. doi: 10.1111/ejh.12684. Epub 2015 Oct 13. Eur J Haematol. 2016. PMID: 26384085

82

Interferon-α induces marked alterations in circulating regulatory T cells, NK cell subsets, and dendritic cells in patients with JAK2V617F-positive essential thrombocythemia and polycythemia vera.

Riley CH, Brimnes MK, Hansen M, Jensen MK, Hasselbalch HC, Kjaer L, Straten PT, Svane IM. Riley CH, et al. Among authors: hasselbalch hc. Eur J Haematol. 2016 Jul;97(1):83-92. doi: 10.1111/ejh.12687. Epub 2015 Nov 26. Eur J Haematol. 2016. PMID: 26385526

83

A 7-Gene Signature Depicts the Biochemical Profile of Early Prefibrotic Myelofibrosis.

Skov V, Burton M, Thomassen M, Stauffer Larsen T, Riley CH, Brinch Madelung A, Kjær L, Bondo H, Stamp I, Ehinger M, Dahl-Sørensen R, Brochmann N, Nielsen K, Thiele J, Jensen MK, Weis Bjerrum O, Kruse TA, Hasselbalch HC. Skov V, et al. Among authors: hasselbalch hc. PLoS One. 2016 Aug 31;11(8):e0161570. doi: 10.1371/journal.pone.0161570. eCollection 2016. PLoS One. 2016. PMID: 27579896 Free PMC article.

84

Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib.

Bjørn ME, Hasselbalch HC. Bjørn ME, et al. Among authors: hasselbalch hc. Expert Rev Hematol. 2017 May;10(5):393-404. doi: 10.1080/17474086.2017.1284583. Epub 2017 Apr 12. Expert Rev Hematol. 2017. PMID: 28402197 Review.

85

Molecular profiling as a novel tool to predict response to interferon-α2 in MPNs: The proof of concept in early myelofibrosis.

Hasselbalch HC. Hasselbalch HC. Cancer. 2017 Jul 15;123(14):2600-2603. doi: 10.1002/cncr.30676. Epub 2017 May 18. Cancer. 2017. PMID: 28518284 Free article. No abstract available.

86

Epigenetic changes in myelofibrosis: Distinct methylation changes in the myeloid compartments and in cases with ASXL1 mutations.

Nielsen HM, Andersen CL, Westman M, Kristensen LS, Asmar F, Kruse TA, Thomassen M, Larsen TS, Skov V, Hansen LL, Bjerrum OW, Hasselbalch HC, Punj V, Grønbæk K. Nielsen HM, et al. Among authors: hasselbalch hc. Sci Rep. 2017 Jul 28;7(1):6774. doi: 10.1038/s41598-017-07057-3. Sci Rep. 2017. PMID: 28754985 Free PMC article.

87

Cardiovascular disease in chronic myelomonocytic leukemia: do monocytosis and chronic inflammation predispose to accelerated atherosclerosis?

Elbæk MV, Sørensen AL, Hasselbalch HC. Elbæk MV, et al. Among authors: hasselbalch hc. Ann Hematol. 2019 Jan;98(1):101-109. doi: 10.1007/s00277-018-3489-0. Epub 2018 Sep 4. Ann Hematol. 2019. PMID: 30182347 Clinical Trial.

88

Bridging blood cancers and inflammation: The reduced Cancitis model.

Ottesen JT, Pedersen RK, Sajid Z, Gudmand-Hoeyer J, Bangsgaard KO, Skov V, Kjær L, Knudsen TA, Pallisgaard N, Hasselbalch HC, Andersen M. Ottesen JT, et al. Among authors: hasselbalch hc. J Theor Biol. 2019 Mar 21;465:90-108. doi: 10.1016/j.jtbi.2019.01.001. Epub 2019 Jan 4. J Theor Biol. 2019. PMID: 30615883

89

Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population.

Cordua S, Kjaer L, Skov V, Pallisgaard N, Hasselbalch HC, Ellervik C. Cordua S, et al. Among authors: hasselbalch hc. Blood. 2019 Aug 1;134(5):469-479. doi: 10.1182/blood.2019001113. Epub 2019 Jun 19. Blood. 2019. PMID: 31217187 Free article.

90

Methylation age as a correlate for allele burden, disease status, and clinical response in myeloproliferative neoplasm patients treated with vorinostat.

McPherson S, Greenfield G, Andersen C, Grinfeld J, Hasselbalch HC, Nangalia J, Mills KI, McMullin MF. McPherson S, et al. Among authors: hasselbalch hc. Exp Hematol. 2019 Nov;79:26-34. doi: 10.1016/j.exphem.2019.09.025. Epub 2019 Sep 26. Exp Hematol. 2019. PMID: 31563618 Free article. Clinical Trial.

91

Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer.

Holmström MO, Cordua S, Skov V, Kjær L, Pallisgaard N, Ellervik C, Hasselbalch HC, Andersen MH. Holmström MO, et al. Among authors: hasselbalch hc. Cancer Immunol Immunother. 2020 Feb;69(2):315-324. doi: 10.1007/s00262-019-02473-y. Epub 2020 Jan 8. Cancer Immunol Immunother. 2020. PMID: 31915854 Free PMC article. Review.

92

Data-driven analysis of JAK2V617F kinetics during interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms.

Pedersen RK, Andersen M, Knudsen TA, Sajid Z, Gudmand-Hoeyer J, Dam MJB, Skov V, Kjaer L, Ellervik C, Larsen TS, Hansen D, Pallisgaard N, Hasselbalch HC, Ottesen JT. Pedersen RK, et al. Among authors: hasselbalch hc. Cancer Med. 2020 Mar;9(6):2039-2051. doi: 10.1002/cam4.2741. Epub 2020 Jan 28. Cancer Med. 2020. PMID: 31991066 Free PMC article.

93

Global dynamics of healthy and cancer cells competing in the hematopoietic system.

Andersen M, Hasselbalch HC, Kjær L, Skov V, Ottesen JT. Andersen M, et al. Among authors: hasselbalch hc. Math Biosci. 2020 Aug;326:108372. doi: 10.1016/j.mbs.2020.108372. Epub 2020 May 19. Math Biosci. 2020. PMID: 32442449

94

Early detection of myeloproliferative neoplasms in a Danish general population study.

Cordua S, Kjaer L, Skov V, Pallisgaard N, Kefala M, Gjerdrum LMR, Hasselbalch HC, Ellervik C. Cordua S, et al. Among authors: hasselbalch hc. Leukemia. 2021 Sep;35(9):2706-2709. doi: 10.1038/s41375-021-01159-8. Epub 2021 Feb 15. Leukemia. 2021. PMID: 33589756 No abstract available.

95

COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon.

Hasselbalch HC, Skov V, Kjær L, Ellervik C, Poulsen A, Poulsen TD, Nielsen CH. Hasselbalch HC, et al. Cytokine Growth Factor Rev. 2021 Aug;60:28-45. doi: 10.1016/j.cytogfr.2021.03.006. Epub 2021 Apr 14. Cytokine Growth Factor Rev. 2021. PMID: 33992887 Free PMC article. Review.

96

Data-driven analysis of the kinetics of the JAK2V617F allele burden and blood cell counts during hydroxyurea treatment of patients with polycythemia vera, essential thrombocythemia, and primary myelofibrosis.

Dam MJB, Pedersen RK, Knudsen TA, Andersen M, Skov V, Kjaer L, Hasselbalch HC, Ottesen JT. Dam MJB, et al. Among authors: hasselbalch hc. Eur J Haematol. 2021 Dec;107(6):624-633. doi: 10.1111/ejh.13700. Epub 2021 Sep 30. Eur J Haematol. 2021. PMID: 34411333 Clinical Trial.

97

Lower CXCR3 expression in both patients with neovascular AMD and advanced stages of chronic myeloproliferative blood cancers.

Liisborg C, Skov V, Kjær L, Hasselbalch HC, Lykke Sørensen T. Liisborg C, et al. Among authors: hasselbalch hc. PLoS One. 2022 Jun 16;17(6):e0269960. doi: 10.1371/journal.pone.0269960. eCollection 2022. PLoS One. 2022. PMID: 35709177 Free PMC article.

98

Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives.

Hasselbalch H, Skov V, Kjær L, Larsen MK, Knudsen TA, Lucijanić M, Kusec R. Hasselbalch H, et al. Cancers (Basel). 2022 Nov 9;14(22):5495. doi: 10.3390/cancers14225495. Cancers (Basel). 2022. PMID: 36428587 Free PMC article.

99

Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment.

Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, Dulicek P, Illes A, Pylypenko H, Sivcheva L, Mayer J, Yablokova V, Krejcy K, Empson V, Hasselbalch HC, Kralovics R, Kiladjian JJ; PROUD-PV Study Group. Gisslinger H, et al. Among authors: hasselbalch hc. Leukemia. 2023 Oct;37(10):2129-2132. doi: 10.1038/s41375-023-02008-6. Epub 2023 Aug 26. Leukemia. 2023. PMID: 37634011 Free PMC article. No abstract available.

100

[The myelodysplastic syndrome I. Pathogenesis, clinical symptoms, diagnosis and differential diagnosis].

Hasselbalch HC, Juhl BR, Hansen PB. Hasselbalch HC, et al. Ugeskr Laeger. 2002 Jan 21;164(4):476-9. Ugeskr Laeger. 2002. PMID: 11838417 Review. Danish.

101

Successful treatment of anemia in idiopathic myelofibrosis with recombinant human erythropoietin.

Hasselbalch HC, Clausen NT, Jensen BA. Hasselbalch HC, et al. Am J Hematol. 2002 Jun;70(2):92-9. doi: 10.1002/ajh.10076. Am J Hematol. 2002. PMID: 12111781 Free article. Clinical Trial.

102

Collagen metabolism and enzymes of the urokinase plasminogen activator system in chronic myeloproliferative disorders: correlation between plasma-soluble urokinase plasminogen activator receptor and serum markers for collagen metabolism.

Jensen MK, Riisbro R, Holten-Andersen MN, Brown Pde N, Junker P, Brünner N, Hasselbalch HC. Jensen MK, et al. Among authors: hasselbalch hc. Eur J Haematol. 2003 Oct;71(4):276-82. doi: 10.1034/j.1600-0609.2003.00134.x. Eur J Haematol. 2003. PMID: 12950237

103

Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis.

Hasselbalch HC, Bjerrum OW, Jensen BA, Clausen NT, Hansen PB, Birgens H, Therkildsen MH, Ralfkiaer E. Hasselbalch HC, et al. Am J Hematol. 2003 Dec;74(4):238-42. doi: 10.1002/ajh.10431. Am J Hematol. 2003. PMID: 14635203 Free article. Clinical Trial.

104

A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life.

Samuelsson J, Hasselbalch H, Bruserud O, Temerinac S, Brandberg Y, Merup M, Linder O, Bjorkholm M, Pahl HL, Birgegard G; Nordic Study Group for Myeloproliferative Disorders. Samuelsson J, et al. Cancer. 2006 Jun 1;106(11):2397-405. doi: 10.1002/cncr.21900. Cancer. 2006. PMID: 16639737 Free article. Clinical Trial.

105

The mevalonate pathway as a therapeutic target in the Ph-negative chronic myeloproliferative disorders.

Hasselbalch HC, Riley CH. Hasselbalch HC, et al. Curr Drug Targets. 2007 Feb;8(2):247-56. doi: 10.2174/138945007779940133. Curr Drug Targets. 2007. PMID: 17305502 Review.

106

Bone marrow histomorphology and JAK2 mutation status in essential thrombocythemia.

Stauffer Larsen T, Hasselbalch HC, Pallisgaard N, Møller MB. Stauffer Larsen T, et al. Among authors: hasselbalch hc. APMIS. 2007 Nov;115(11):1267-73. doi: 10.1111/j.1600-0643.2007.00807.x. APMIS. 2007. PMID: 18092959

107

[Tyrosine kinase inhibitors in the treatment of polycythemia vera and related conditions. Danish Society of Hematology].

Larsen TS, Hasselbalch HC; Dansk Haematologisk Selskab. Larsen TS, et al. Among authors: hasselbalch hc. Ugeskr Laeger. 2008 Mar 17;170(12):1031. Ugeskr Laeger. 2008. PMID: 18397649 Danish. No abstract available.

108

High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden.

Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC. Larsen TS, et al. Among authors: hasselbalch hc. Hematology. 2008 Apr;13(2):71-6. doi: 10.1179/102453308X315960. Hematology. 2008. PMID: 18616871 Free article.

109

Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence.

Lataillade JJ, Pierre-Louis O, Hasselbalch HC, Uzan G, Jasmin C, Martyré MC, Le Bousse-Kerdilès MC; French INSERM and the European EUMNET Networks on Myelofibrosis. Lataillade JJ, et al. Among authors: hasselbalch hc. Blood. 2008 Oct 15;112(8):3026-35. doi: 10.1182/blood-2008-06-158386. Epub 2008 Jul 31. Blood. 2008. PMID: 18669872 Free article. Review.

110

A novel immunohistochemical sequential multi-labelling and erasing technique enables epitope characterization of bone marrow pericytes in primary myelofibrosis.

Madelung A, Bzorek M, Bondo H, Zetterberg E, Bjerrum OW, Hasselbalch HC, Scheding S, Ralfkiaer E. Madelung A, et al. Among authors: hasselbalch hc. Histopathology. 2012 Mar;60(4):554-60. doi: 10.1111/j.1365-2559.2011.04104.x. Epub 2012 Jan 17. Histopathology. 2012. PMID: 22250648

111

Survival of patients with chronic myeloproliferative neoplasms and new primary cancers: a population-based cohort study.

Frederiksen H, Farkas DK, Christiansen CF, Larsen TS, Hasselbalch HC, Stentoft J, Sørensen HT. Frederiksen H, et al. Among authors: hasselbalch hc. Lancet Haematol. 2015 Jul;2(7):e289-96. doi: 10.1016/S2352-3026(15)00092-7. Epub 2015 Jun 11. Lancet Haematol. 2015. PMID: 26688384

112

Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms.

Hansen IO, Sørensen AL, Hasselbalch HC. Hansen IO, et al. Among authors: hasselbalch hc. Eur J Haematol. 2017 Jan;98(1):75-84. doi: 10.1111/ejh.12787. Epub 2016 Sep 4. Eur J Haematol. 2017. PMID: 27471124

113

Cancer immune therapy for myeloid malignancies: present and future.

Holmström MO, Hasselbalch HC. Holmström MO, et al. Among authors: hasselbalch hc. Semin Immunopathol. 2019 Jan;41(1):97-109. doi: 10.1007/s00281-018-0693-x. Epub 2018 Jul 9. Semin Immunopathol. 2019. PMID: 29987478 Review.

114

Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study Group.

Birgegard G, Samuelsson J, Ahlstrand E, Ejerblad E, Enevold C, Ghanima W, Hasselbalch H, Nielsen CH, Knutsen H, Pedersen OB, Sørensen A, Andreasson B. Birgegard G, et al. Eur J Haematol. 2019 Mar;102(3):235-240. doi: 10.1111/ejh.13198. Epub 2019 Jan 1. Eur J Haematol. 2019. PMID: 30472746

115

B-cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: Influence of ruxolitinib, interferon-α2, or combination treatment.

Sørensen AL, Bjørn ME, Riley CH, Holmstrøm M, Andersen MH, Svane IM, Mikkelsen SU, Skov V, Kjaer L, Hasselbalch HC, Nielsen CH. Sørensen AL, et al. Among authors: hasselbalch hc. Eur J Haematol. 2019 Oct;103(4):351-361. doi: 10.1111/ejh.13292. Epub 2019 Aug 18. Eur J Haematol. 2019. PMID: 31297883 Clinical Trial.

116

The red blood cell count and the erythrocyte sedimentation rate in the diagnosis of polycythaemia vera.

Nersesjan V, Zervides KA, Sørensen AL, Kjaer L, Skov V, Hasselbalch HC. Nersesjan V, et al. Among authors: hasselbalch hc. Eur J Haematol. 2020 Jan;104(1):46-54. doi: 10.1111/ejh.13334. Epub 2019 Nov 22. Eur J Haematol. 2020. PMID: 31584701

117

[Rationales for using JAK 1/2 inhibitors in severely afflicted patients with COVID-19 pneumonia].

Hasselbalch HC, Poulsen A, Skov V, Kjær L, Nielsen CH, Poulsen TD. Hasselbalch HC, et al. Ugeskr Laeger. 2020 Jun 15;182(25):V04200234. Ugeskr Laeger. 2020. PMID: 32584762 Free article. Review. Danish.

118

Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms.

Holmström MO, Hasselbalch HC, Andersen MH. Holmström MO, et al. Among authors: hasselbalch hc. Cancers (Basel). 2020 Jul 2;12(7):1763. doi: 10.3390/cancers12071763. Cancers (Basel). 2020. PMID: 32630667 Free PMC article. Review.

119

Elevated levels of oxidized nucleosides in individuals with the JAK2V617F mutation from a general population study.

Sørensen AL, Hasselbalch HC, Bjørn ME, Nielsen CH, Cordua S, Skov V, Kjær L, Poulsen HE, Ellervik C. Sørensen AL, et al. Among authors: hasselbalch hc. Redox Biol. 2021 May;41:101895. doi: 10.1016/j.redox.2021.101895. Epub 2021 Feb 13. Redox Biol. 2021. PMID: 33621788 Free PMC article.

120

[Elevated blood cell counts and vascular disease with the myeloproliferative neoplasms as model diseases].

Hasselbalch HC, Knudsen TA, Sørensen AL, Christensen SF, Larsen MK, Bak M, El Fassi D, Cordua S, Brabrand M, Thomsen G, Stentoft J, Starklint J, Ellervik C, Wienecke T, Bruun NE, Eickhardt-Dalbøge CE, Kjær L, Skov V. Hasselbalch HC, et al. Ugeskr Laeger. 2021 Oct 18;183(42):V03210282. Ugeskr Laeger. 2021. PMID: 34709157 Free article. Review. Danish.

121

Clonal haematopoiesis of indeterminate potential and impaired kidney function-A Danish general population study with 11 years follow-up.

Larsen MK, Skov V, Kjaer L, Møller-Palacino NA, Pedersen RK, Andersen M, Ottesen JT, Cordua S, Poulsen HE, Dahl M, Knudsen TA, Eickhardt-Dalbøge CS, Koschmieder S, Pedersen KM, Çolak Y, Bojesen SE, Nordestgaard BG, Stiehl T, Hasselbalch HC, Ellervik C. Larsen MK, et al. Among authors: hasselbalch hc. Eur J Haematol. 2022 Nov;109(5):576-585. doi: 10.1111/ejh.13845. Epub 2022 Aug 21. Eur J Haematol. 2022. PMID: 36054308 Free PMC article.

122

The gut microbiota in patients with polycythemia vera is distinct from that of healthy controls and varies by treatment.

Eickhardt-Dalbøge CS, Ingham AC, Andersen LO, Nielsen HV, Fuursted K, Stensvold CR, Larsen MK, Kjær L, Christensen SF, Knudsen TA, Skov V, Ellervik C, Olsen LR, Hasselbalch HC, Nielsen XC, Christensen JJE. Eickhardt-Dalbøge CS, et al. Among authors: hasselbalch hc. Blood Adv. 2023 Jul 11;7(13):3326-3337. doi: 10.1182/bloodadvances.2022008555. Blood Adv. 2023. PMID: 36260736 Free PMC article.

123

Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms.

Hasselbalch HC, Junker P, Skov V, Kjær L, Knudsen TA, Larsen MK, Holmström MO, Andersen MH, Jensen C, Karsdal MA, Willumsen N. Hasselbalch HC, et al. Cancers (Basel). 2023 Aug 29;15(17):4323. doi: 10.3390/cancers15174323. Cancers (Basel). 2023. PMID: 37686599 Free PMC article. Review.

124

Pronounced gut microbiota signatures in patients with JAK2V617F-positive essential thrombocythemia.

Eickhardt-Dalbøge CS, Ingham AC, Nielsen HV, Fuursted K, Stensvold CR, Andersen LO, Larsen MK, Kjær L, Christensen SF, Knudsen TA, Skov V, Ellervik C, Olsen LR, Hasselbalch HC, Elmer Christensen JJ, Nielsen XC. Eickhardt-Dalbøge CS, et al. Among authors: hasselbalch hc. Microbiol Spectr. 2023 Oct 17;11(5):e0066223. doi: 10.1128/spectrum.00662-23. Epub 2023 Sep 11. Microbiol Spectr. 2023. PMID: 37695126 Free PMC article.

125

Idiopathic myelofibrosis--an update with particular reference to clinical aspects and prognosis.

Hasselbalch HC. Hasselbalch HC. Int J Clin Lab Res. 1993;23(3):124-38. doi: 10.1007/BF02592297. Int J Clin Lab Res. 1993. PMID: 8400333 Review.

126

Idiopathic myelofibrosis. Clinical aspects and studies on extracellular matrix metabolism.

Hasselbalch HC. Hasselbalch HC. Dan Med Bull. 1993 Mar;40(1):39-55. Dan Med Bull. 1993. PMID: 8472598 Review. No abstract available.

127

Fatal virus-associated hemophagocytic syndrome associated with coexistent chronic active hepatitis B and acute hepatitis C virus infection.

Faurschou M, Nielsen OJ, Hansen PB, Juhl BR, Hasselbalch H. Faurschou M, et al. Am J Hematol. 1999 Jun;61(2):135-8. doi: 10.1002/(sici)1096-8652(199906)61:2<135::aid-ajh11>3.0.co;2-e. Am J Hematol. 1999. PMID: 10367794 Free article.

128

[STI571 (Glivec)--a new drug for the treatment of chronic myeloid leukemia].

Hasselbalch HC. Hasselbalch HC. Ugeskr Laeger. 2002 May 27;164(22):2914-7. Ugeskr Laeger. 2002. PMID: 12082821 Review. Danish.

129

Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan.

Nielsen I, Hasselbalch HC. Nielsen I, et al. Among authors: hasselbalch hc. Am J Hematol. 2003 Sep;74(1):26-31. doi: 10.1002/ajh.10375. Am J Hematol. 2003. PMID: 12949887 Free article.

130

WHO classification 2008 of myeloproliferative neoplasms: a workshop learning effect--the Danish experience.

Madelung AB, Bondo H, Stamp I, Løvgreen P, Nielsen SL, Falensteen A, Knudsen H, Svendsen KD, Lange T, Ralfkiaer E, Nielsen K, Hasselbalch H, Thiele J. Madelung AB, et al. APMIS. 2015 Sep;123(9):787-92. doi: 10.1111/apm.12417. Epub 2015 Jul 22. APMIS. 2015. PMID: 26200697

131

Mediators of Inflammation in Myeloproliferative Neoplasms: State of the Art.

Hermouet S, Hasselbalch HC, Čokić V. Hermouet S, et al. Among authors: hasselbalch hc. Mediators Inflamm. 2015;2015:964613. doi: 10.1155/2015/964613. Epub 2015 Nov 23. Mediators Inflamm. 2015. PMID: 26681841 Free PMC article. No abstract available.

132

Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment.

Kjær L, Cordua S, Holmström MO, Thomassen M, Kruse TA, Pallisgaard N, Larsen TS, de Stricker K, Skov V, Hasselbalch HC. Kjær L, et al. Among authors: hasselbalch hc. PLoS One. 2016 Oct 20;11(10):e0165336. doi: 10.1371/journal.pone.0165336. eCollection 2016. PLoS One. 2016. PMID: 27764253 Free PMC article.

133

Whole Blood Gene Expression Profiling in patients undergoing colon cancer surgery identifies differential expression of genes involved in immune surveillance, inflammation and carcinogenesis.

Watt SK, Hasselbalch HC, Skov V, Kjær L, Thomassen M, Kruse TA, Burton M, Gögenur I. Watt SK, et al. Among authors: hasselbalch hc. Surg Oncol. 2018 Jun;27(2):208-215. doi: 10.1016/j.suronc.2018.03.002. Epub 2018 Mar 27. Surg Oncol. 2018. PMID: 29937173

134

Classification and Personalized Prognosis in Myeloproliferative Neoplasms.

Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N, Cantrill R, Godfrey AL, Papaemmanuil E, Gundem G, MacLean C, Cook J, O'Neil L, O'Meara S, Teague JW, Butler AP, Massie CE, Williams N, Nice FL, Andersen CL, Hasselbalch HC, Guglielmelli P, McMullin MF, Vannucchi AM, Harrison CN, Gerstung M, Green AR, Campbell PJ. Grinfeld J, et al. Among authors: hasselbalch hc. N Engl J Med. 2018 Oct 11;379(15):1416-1430. doi: 10.1056/NEJMoa1716614. N Engl J Med. 2018. PMID: 30304655 Free PMC article.

135

Statin treatment, oxidative stress and inflammation in a Danish population.

Sørensen AL, Hasselbalch HC, Nielsen CH, Poulsen HE, Ellervik C. Sørensen AL, et al. Among authors: hasselbalch hc. Redox Biol. 2019 Feb;21:101088. doi: 10.1016/j.redox.2018.101088. Epub 2018 Dec 21. Redox Biol. 2019. PMID: 30594900 Free PMC article.

136

High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals.

Holmström MO, Ahmad SM, Klausen U, Bendtsen SK, Martinenaite E, Riley CH, Svane IM, Kjær L, Skov V, Ellervik C, Pallisgaard N, Hasselbalch HC, Andersen MH. Holmström MO, et al. Among authors: hasselbalch hc. Blood Cancer J. 2019 Jan 17;9(2):8. doi: 10.1038/s41408-018-0166-4. Blood Cancer J. 2019. PMID: 30655510 Free PMC article.

137

Neo-antigen specific memory T-cell responses in healthy individuals.

Holmström MO, Hasselbalch HC, Andersen MH. Holmström MO, et al. Among authors: hasselbalch hc. Oncoimmunology. 2019 Apr 19;8(7):1599640. doi: 10.1080/2162402X.2019.1599640. eCollection 2019. Oncoimmunology. 2019. PMID: 31143522 Free PMC article.

138

Smoking impairs molecular response, and reduces overall survival in patients with chronic myeloproliferative neoplasms: A retrospective cohort study.

Sørensen AL, Knudsen TA, Skov V, Kjaer L, Holm N, Ellervik C, Hasselbalch HC. Sørensen AL, et al. Among authors: hasselbalch hc. Br J Haematol. 2021 Apr;193(1):83-92. doi: 10.1111/bjh.17130. Epub 2020 Nov 10. Br J Haematol. 2021. PMID: 33169852

139

The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms.

Hasselbalch HC, Elvers M, Schafer AI. Hasselbalch HC, et al. Blood. 2021 Apr 22;137(16):2152-2160. doi: 10.1182/blood.2020008109. Blood. 2021. PMID: 33649757 Free article. Review.

140

Retinal drusen in patients with chronic myeloproliferative blood cancers are associated with an increased proportion of senescent T cells and signs of an aging immune system.

Liisborg C, Skov V, Kjær L, Hasselbalch HC, Sørensen TL. Liisborg C, et al. Among authors: hasselbalch hc. Aging (Albany NY). 2021 Dec 26;13(24):25763-25777. doi: 10.18632/aging.203803. Epub 2021 Dec 26. Aging (Albany NY). 2021. PMID: 34954692 Free PMC article.

141

Patients with MPNs and retinal drusen show signs of complement system dysregulation and a high degree of chronic low-grade inflammation.

Liisborg C, Skov V, Kjær L, Hasselbalch HC, Sørensen TL. Liisborg C, et al. Among authors: hasselbalch hc. EClinicalMedicine. 2021 Dec 25;43:101248. doi: 10.1016/j.eclinm.2021.101248. eCollection 2022 Jan. EClinicalMedicine. 2021. PMID: 35128362 Free PMC article.

142

Patients With Myeloproliferative Neoplasms Harbor High Frequencies of CD8 T Cell-Platelet Aggregates Associated With T Cell Suppression.

Carnaz Simões AM, Holmström MO, Aehnlich P, Rahbech A, Radziwon-Balicka A, Zamora C, Wirenfeldt Klausen T, Skov V, Kjær L, Ellervik C, Fassi DE, Vidal S, Hasselbalch HC, Andersen MH, Thor Straten P. Carnaz Simões AM, et al. Among authors: hasselbalch hc. Front Immunol. 2022 May 6;13:866610. doi: 10.3389/fimmu.2022.866610. eCollection 2022. Front Immunol. 2022. PMID: 35603202 Free PMC article.

143

Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine.

Gigoux M, Holmström MO, Zappasodi R, Park JJ, Pourpe S, Bozkus CC, Mangarin LMB, Redmond D, Verma S, Schad S, George MM, Venkatesh D, Ghosh A, Hoyos D, Molvi Z, Kamaz B, Marneth AE, Duke W, Leventhal MJ, Jan M, Ho VT, Hobbs GS, Knudsen TA, Skov V, Kjær L, Larsen TS, Hansen DL, Lindsley RC, Hasselbalch H, Grauslund JH, Lisle TL, Met Ö, Wilkinson P, Greenbaum B, Sepulveda MA, Chan T, Rampal R, Andersen MH, Abdel-Wahab O, Bhardwaj N, Wolchok JD, Mullally A, Merghoub T. Gigoux M, et al. Sci Transl Med. 2022 Jun 15;14(649):eaba4380. doi: 10.1126/scitranslmed.aba4380. Epub 2022 Jun 15. Sci Transl Med. 2022. PMID: 35704596 Free PMC article.

144

Coronary artery- and aortic valve calcifications in patients with Philadelphia-negative myeloproliferative neoplasms.

Solli CN, Chamat-Hedemand S, Elming H, Ngo A, Kjær L, Skov V, Sørensen AL, Ellervik C, Fuchs A, Sigvardsen PE, Kühl JT, Kofoed KF, Nordestgaard BG, Hasselbalch H, Bruun NE. Solli CN, et al. Int J Cardiol. 2022 Oct 1;364:112-118. doi: 10.1016/j.ijcard.2022.06.029. Epub 2022 Jun 16. Int J Cardiol. 2022. PMID: 35716942 Free article.

145

Whole blood transcriptional profiling reveals highly deregulated atherosclerosis genes in Philadelphia-chromosome negative myeloproliferative neoplasms.

Skov V, Thomassen M, Kjaer L, Larsen MK, Knudsen TA, Ellervik C, Kruse TA, Hasselbalch HC. Skov V, et al. Among authors: hasselbalch hc. Eur J Haematol. 2023 Nov;111(5):805-814. doi: 10.1111/ejh.14081. Epub 2023 Aug 28. Eur J Haematol. 2023. PMID: 37640394

146

Proof of concept of triple COMBI therapy to prohibit MPN progression to AML.

Hasselbalch HC, Skov V, Kjaer L, Larsen MK. Hasselbalch HC, et al. Br J Haematol. 2024 Jan;204(1):16-18. doi: 10.1111/bjh.19173. Epub 2023 Nov 13. Br J Haematol. 2024. PMID: 37957927

147

Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera.

Sørensen AL, Skov V, Kjær L, Bjørn ME, Eickhardt-Dalbøge CS, Larsen MK, Nielsen CH, Thomsen C, Rahbek Gjerdrum LM, Knudsen TA, Ellervik C, Overgaard UM, Andersen CL, Hasselbalch H. Sørensen AL, et al. Blood Adv. 2024 Oct 22;8(20):5416-5425. doi: 10.1182/bloodadvances.2024013170. Blood Adv. 2024. PMID: 39163611 Free PMC article. Clinical Trial.

148

Elevated plasma levels of TIMP-1 correlate with plasma suPAR/uPA in patients with chronic myeloproliferative disorders.

Jensen MK, Holten-Andersen MN, Riisbro R, de Nully Brown P, Larsen MB, Kjeldsen L, Heickendorff L, Brünner N, Hasselbalch HC. Jensen MK, et al. Among authors: hasselbalch hc. Eur J Haematol. 2003 Nov;71(5):377-84. doi: 10.1034/j.1600-0609.2003.00096.x. Eur J Haematol. 2003. PMID: 14667201

149

[New molecular markers within the chronic myeloproliferative disorders. II: the JAK2 mutation].

Larsen TS, Pallisgaard N, Christensen JH, Gram-Hansen P, Kerndrup GB, Møller MB, Hasselbalch HC. Larsen TS, et al. Among authors: hasselbalch hc. Ugeskr Laeger. 2006 Sep 25;168(39):3299-303. Ugeskr Laeger. 2006. PMID: 17032592 Review. Danish.

150

Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden.

Larsen TS, Pallisgaard N, de Stricker K, Møller MB, Hasselbalch HC. Larsen TS, et al. Among authors: hasselbalch hc. Hematology. 2009 Feb;14(1):11-5. doi: 10.1179/102453309X385188. Hematology. 2009. PMID: 19154659 Free article.

151

Eosinophilia in routine blood samples and the subsequent risk of hematological malignancies and death.

Andersen CL, Siersma VD, Hasselbalch HC, Lindegaard H, Vestergaard H, Felding P, de Fine Olivarius N, Bjerrum OW. Andersen CL, et al. Among authors: hasselbalch hc. Am J Hematol. 2013 Oct;88(10):843-7. doi: 10.1002/ajh.23515. Epub 2013 Aug 1. Am J Hematol. 2013. PMID: 23765950 Free article. Clinical Trial.

152

A phase II study of vorinostat (MK-0683) in patients with primary myelofibrosis and post-polycythemia vera myelofibrosis.

Andersen CL, Mortensen NB, Klausen TW, Vestergaard H, Bjerrum OW, Hasselbalch HC. Andersen CL, et al. Among authors: hasselbalch hc. Haematologica. 2014 Jan;99(1):e5-7. doi: 10.3324/haematol.2013.096669. Haematologica. 2014. PMID: 24425692 Free PMC article. Clinical Trial. No abstract available.

153

Eosinophilia in routine blood samples as a biomarker for solid tumor development - A study based on the Copenhagen Primary Care Differential Count (CopDiff) Database.

Andersen CL, Siersma VD, Hasselbalch HC, Lindegaard H, Vestergaard H, Felding P, de Fine Olivarius N, Bjerrum OW. Andersen CL, et al. Among authors: hasselbalch hc. Acta Oncol. 2014 Sep;53(9):1245-50. doi: 10.3109/0284186X.2014.887857. Epub 2014 Mar 10. Acta Oncol. 2014. PMID: 24913152

154

Whole-exome sequencing and genome-wide methylation analyses identify novel disease associated mutations and methylation patterns in idiopathic hypereosinophilic syndrome.

Andersen CL, Nielsen HM, Kristensen LS, Søgaard A, Vikeså J, Jønson L, Nielsen FC, Hasselbalch H, Bjerrum OW, Punj V, Grønbæk K. Andersen CL, et al. Oncotarget. 2015 Dec 1;6(38):40588-97. doi: 10.18632/oncotarget.5845. Oncotarget. 2015. PMID: 26497854 Free PMC article.

155

The JAK2V617F and CALR exon 9 mutations are shared immunogenic neoantigens in hematological malignancy.

Holmström MO, Hasselbalch HC, Andersen MH. Holmström MO, et al. Among authors: hasselbalch hc. Oncoimmunology. 2017 Aug 2;6(11):e1358334. doi: 10.1080/2162402X.2017.1358334. eCollection 2017. Oncoimmunology. 2017. PMID: 29147619 Free PMC article.

156

Ocular Manifestations in Patients with Philadelphia-Negative Myeloproliferative Neoplasms.

Liisborg C, Hasselbalch HC, Sørensen TL. Liisborg C, et al. Among authors: hasselbalch hc. Cancers (Basel). 2020 Mar 2;12(3):573. doi: 10.3390/cancers12030573. Cancers (Basel). 2020. PMID: 32121664 Free PMC article. Review.

157

Aberrations of chromosome 6 in 193 newly diagnosed untreated cases of chronic lymphocytic leukemia.

Philip P, Geisler C, Hansen MM, Hasselbalch H, Christensen BE, Drivsholm A, Lund B, Nielsen JB, Jensen KB, Andersen E. Philip P, et al. Cancer Genet Cytogenet. 1991 May;53(1):35-43. doi: 10.1016/0165-4608(91)90112-8. Cancer Genet Cytogenet. 1991. PMID: 2036638

158

[Immunosuppressive treatment of the myelodysplastic syndrome].

Larsen MS, Hasselbalch HC. Larsen MS, et al. Among authors: hasselbalch hc. Ugeskr Laeger. 2003 Jun 23;165(26):2654-7. Ugeskr Laeger. 2003. PMID: 12886548 Danish.

159

[Aquagenic pruritus from polycythaemia vera--treatment with paroxetine, a selective serotonin reuptake inhibitor].

Kümler T, Hedlund D, Hast R, Hasselbalch HC. Kümler T, et al. Among authors: hasselbalch hc. Ugeskr Laeger. 2008 Sep 15;170(38):2981. Ugeskr Laeger. 2008. PMID: 18808757 Danish.

160

Characterization of blood donors with high haemoglobin concentration.

Magnussen K, Hasselbalch HC, Ullum H, Bjerrum OW. Magnussen K, et al. Among authors: hasselbalch hc. Vox Sang. 2013 Feb;104(2):110-4. doi: 10.1111/j.1423-0410.2012.01644.x. Epub 2012 Aug 15. Vox Sang. 2013. PMID: 22891616

161

Risk of lymphoma and solid cancer among patients with rheumatoid arthritis in a primary care setting.

Andersen CL, Lindegaard H, Vestergaard H, Siersma VD, Hasselbalch HC, de Fine Olivarius N, Bjerrum OW, Junker P. Andersen CL, et al. Among authors: hasselbalch hc. PLoS One. 2014 Jun 10;9(6):e99388. doi: 10.1371/journal.pone.0099388. eCollection 2014. PLoS One. 2014. PMID: 24914777 Free PMC article.

162

Telomerase Inhibitor Imetelstat in Essential Thrombocythemia and Myelofibrosis.

Bjørn ME, Nielsen CH, Hasselbalch HC. Bjørn ME, et al. Among authors: hasselbalch hc. N Engl J Med. 2015 Dec 24;373(26):2579-80. doi: 10.1056/NEJMc1512663. N Engl J Med. 2015. PMID: 26699178 Free article. No abstract available.

163

Associations between fatigue, physical activity, and QoL in patients with myeloproliferative neoplasms.

Tolstrup Larsen R, Tang LH, Brochmann N, Meulengracht Flachs E, Illemann Christensen A, Hasselbalch HC, Zwisler AD. Tolstrup Larsen R, et al. Among authors: hasselbalch hc. Eur J Haematol. 2018 Jun;100(6):550-559. doi: 10.1111/ejh.13048. Epub 2018 Apr 6. Eur J Haematol. 2018. PMID: 29464777

164

The effectiveness of exercise-based rehabilitation to patients with myeloproliferative neoplasms-An explorative study.

Pedersen KM, Zangger G, Brochmann N, Grønfeldt BM, Zwisler AD, Hasselbalch HC, Tang LH. Pedersen KM, et al. Among authors: hasselbalch hc. Eur J Cancer Care (Engl). 2018 Sep;27(5):e12865. doi: 10.1111/ecc.12865. Epub 2018 Jun 11. Eur J Cancer Care (Engl). 2018. PMID: 29888803

165

Dynamics of competing heterogeneous clones in blood cancers explains multiple observations - a mathematical modeling approach.

Bangsgaard KO, Andersen M, Skov V, Kjær L, Hasselbalch HC, Ottesen JT. Bangsgaard KO, et al. Among authors: hasselbalch hc. Math Biosci Eng. 2020 Nov 4;17(6):7645-7670. doi: 10.3934/mbe.2020389. Math Biosci Eng. 2020. PMID: 33378913 Free article.

166

Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses.

Knudsen TA, Skov V, Stevenson K, Werner L, Duke W, Laurore C, Gibson CJ, Nag A, Thorner AR, Wollison B, Hansen DL, Ellervik C, El Fassi D, de Stricker K, Ocias LF, Brabrand M, Bjerrum OW, Overgaard UM, Frederiksen M, Kristensen TK, Kruse TA, Thomassen M, Mourits-Andersen T, Severinsen MT, Stentoft J, Starklint J, Neuberg DS, Kjaer L, Larsen TS, Hasselbalch HC, Lindsley RC, Mullally A. Knudsen TA, et al. Among authors: hasselbalch hc. Blood Adv. 2022 Apr 12;6(7):2107-2119. doi: 10.1182/bloodadvances.2021004856. Blood Adv. 2022. PMID: 34507355 Free PMC article. Clinical Trial.

167

Interferon alpha-2 treatment reduces circulating neutrophil extracellular trap levels in myeloproliferative neoplasms.

Massarenti L, Knudsen TA, Enevold C, Skov V, Kjaer L, Larsen MK, Larsen TS, Hansen DL, Hasselbalch HC, Nielsen CH. Massarenti L, et al. Among authors: hasselbalch hc. Br J Haematol. 2023 Jul;202(2):318-327. doi: 10.1111/bjh.18845. Epub 2023 May 22. Br J Haematol. 2023. PMID: 37211985

168

Prevalence and impact of additional CHIP mutations in JAK2V617F-positive ischaemic cerebrovascular patients.

Kristiansen MH, Skov V, Larsen MK, Kjær L, Nielsen CH, Hasselbalch HC, Wienecke T. Kristiansen MH, et al. Among authors: hasselbalch hc. Br J Haematol. 2025 Sep;207(3):1029-1037. doi: 10.1111/bjh.20242. Epub 2025 Jul 23. Br J Haematol. 2025. PMID: 40701821 Free PMC article.

169

Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders.

Jensen MK, de Nully Brown P, Lund BV, Nielsen OJ, Hasselbalch HC. Jensen MK, et al. Among authors: hasselbalch hc. Br J Haematol. 2000 Jul;110(1):116-24. doi: 10.1046/j.1365-2141.2000.02030.x. Br J Haematol. 2000. PMID: 10930987

170

Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area.

Jensen MK, de Nully Brown P, Nielsen OJ, Hasselbalch HC. Jensen MK, et al. Among authors: hasselbalch hc. Eur J Haematol. 2000 Aug;65(2):132-9. doi: 10.1034/j.1600-0609.2000.90236.x. Eur J Haematol. 2000. PMID: 10966175

171

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.

Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, Andersen I, Schmidt K, Andersen TM, Peterslund NA, Birgens HS, Plesner T, Pedersen BB, Hasselbalch HC. Braendstrup P, et al. Among authors: hasselbalch hc. Am J Hematol. 2005 Apr;78(4):275-80. doi: 10.1002/ajh.20276. Am J Hematol. 2005. PMID: 15795920 Free article.

172

The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option.

El Fassi D, Nielsen CH, Hasselbalch HC, Hegedüs L. El Fassi D, et al. Among authors: hasselbalch hc. Eur J Endocrinol. 2006 May;154(5):623-32. doi: 10.1530/eje.1.02140. Eur J Endocrinol. 2006. PMID: 16645007 Review.

173

B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study.

El Fassi D, Nielsen CH, Bonnema SJ, Hasselbalch HC, Hegedüs L. El Fassi D, et al. Among authors: hasselbalch hc. J Clin Endocrinol Metab. 2007 May;92(5):1769-72. doi: 10.1210/jc.2006-2388. Epub 2007 Feb 6. J Clin Endocrinol Metab. 2007. PMID: 17284622 Clinical Trial.

174

B-cell depletion with rituximab in the treatment of autoimmune diseases. Graves' ophthalmopathy the latest addition to an expanding family.

Nielsen CH, El Fassi D, Hasselbalch HC, Bendtzen K, Hegedüs L. Nielsen CH, et al. Among authors: hasselbalch hc. Expert Opin Biol Ther. 2007 Jul;7(7):1061-78. doi: 10.1517/14712598.7.7.1061. Expert Opin Biol Ther. 2007. PMID: 17665994 Review.

175

[Eosinophilia--pathogenesis, classification and therapy].

Andersen CL, Vestergaard H, Nørgaard P, Felding P, Pallisgaard N, Rasmussen IH, Hasselbalch HC, Bjerrum OW. Andersen CL, et al. Among authors: hasselbalch hc. Ugeskr Laeger. 2009 Nov 2;171(45):3256-62. Ugeskr Laeger. 2009. PMID: 19887055 Review. Danish.

176

Interferon alpha2 in the treatment of hematological malignancies. Status and perspectives.

Hasselbalch HC. Hasselbalch HC. Curr Drug Targets. 2011 Mar 1;12(3):387-91. doi: 10.2174/138945011794815220. Curr Drug Targets. 2011. PMID: 21143152 No abstract available.

177

[New treatment options for primary immune thrombocytopenia].

Gudbrandsdottir S, Frederiksen H, Birgens HS, Nielsen CH, Nielsen OJ, Stentoft J, Hasselbalch HC. Gudbrandsdottir S, et al. Among authors: hasselbalch hc. Ugeskr Laeger. 2011 Jan 24;173(4):271-4. Ugeskr Laeger. 2011. PMID: 21262171 Danish.

178

[The pathogenesis of primary immune thrombocytopenia].

Gudbrandsdottir S, Frederiksen H, Birgens HS, Nielsen CH, Nielsen OJ, Stentoft J, Hasselbalch HC. Gudbrandsdottir S, et al. Among authors: hasselbalch hc. Ugeskr Laeger. 2011 Jan 24;173(4):274-7. Ugeskr Laeger. 2011. PMID: 21262172 Danish.

179

Interferon alfa in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms.

Hasselbalch HC, Kiladjian JJ, Silver RT. Hasselbalch HC, et al. J Clin Oncol. 2011 Jun 20;29(18):e564-5. doi: 10.1200/JCO.2011.35.6238. Epub 2011 May 16. J Clin Oncol. 2011. PMID: 21576637 No abstract available.

180

Systemic mastocytosis--a systematic review.

Andersen CL, Kristensen TK, Severinsen MT, Møller MB, Vestergaard H, Bergmann OJ, Hasselbalch HC, Bjerrum OW. Andersen CL, et al. Among authors: hasselbalch hc. Dan Med J. 2012 Mar;59(3):A4397. Dan Med J. 2012. PMID: 22381091 Free article.

181

Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia.

Gudbrandsdottir S, Birgens HS, Frederiksen H, Jensen BA, Jensen MK, Kjeldsen L, Klausen TW, Larsen H, Mourits-Andersen HT, Nielsen CH, Nielsen OJ, Plesner T, Pulczynski S, Rasmussen IH, Rønnov-Jessen D, Hasselbalch HC. Gudbrandsdottir S, et al. Among authors: hasselbalch hc. Blood. 2013 Mar 14;121(11):1976-81. doi: 10.1182/blood-2012-09-455691. Epub 2013 Jan 4. Blood. 2013. PMID: 23293082 Free article. Clinical Trial.

182

World Health Organization-defined classification of myeloproliferative neoplasms: morphological reproducibility and clinical correlations--the Danish experience.

Madelung AB, Bondo H, Stamp I, Loevgreen P, Nielsen SL, Falensteen A, Knudsen H, Ehinger M, Dahl-Sørensen R, Mortensen NB, Svendsen KD, Lange T, Ralfkiaer E, Nielsen K, Hasselbalch HC, Thiele J. Madelung AB, et al. Among authors: hasselbalch hc. Am J Hematol. 2013 Dec;88(12):1012-6. doi: 10.1002/ajh.23554. Epub 2013 Sep 30. Am J Hematol. 2013. PMID: 23897670 Free article.

183

A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia.

Birgens H, Frederiksen H, Hasselbalch HC, Rasmussen IH, Nielsen OJ, Kjeldsen L, Larsen H, Mourits-Andersen T, Plesner T, Rønnov-Jessen D, Vestergaard H, Klausen TW, Schöllkopf C. Birgens H, et al. Among authors: hasselbalch hc. Br J Haematol. 2013 Nov;163(3):393-9. doi: 10.1111/bjh.12541. Epub 2013 Aug 24. Br J Haematol. 2013. PMID: 23981017 Clinical Trial.

184

Eosinophilia in routine blood samples as a biomarker for solid tumor development - A study based on The Copenhagen Primary Care Differential Count (CopDiff) Database.

Andersen CL, Siersma VD, Hasselbalch HC, Lindegaard H, Vestergaard H, Felding P, Olivarius Nde F, Bjerrum OW. Andersen CL, et al. Among authors: hasselbalch hc. Acta Oncol. 2013 Dec 20. doi: 10.3109/0284186X.2013.866270. Epub 2013 Dec 20. Acta Oncol. 2013. Retraction in: Acta Oncol. 2014 Apr;53(4):576. doi: 10.3109/0284186X.2013.879685. PMID: 24358991 Retracted.

185

The Copenhagen Primary Care Differential Count (CopDiff) database.

Andersen CL, Siersma VD, Karlslund W, Hasselbalch HC, Felding P, Bjerrum OW, de Fine Olivarius N. Andersen CL, et al. Among authors: hasselbalch hc. Clin Epidemiol. 2014 Jun 12;6:199-211. doi: 10.2147/CLEP.S60991. eCollection 2014. Clin Epidemiol. 2014. PMID: 24966694 Free PMC article.

186

Association of the blood eosinophil count with hematological malignancies and mortality.

Andersen CL, Siersma VD, Hasselbalch HC, Vestergaard H, Mesa R, Felding P, Olivarius ND, Bjerrum OW. Andersen CL, et al. Among authors: hasselbalch hc. Am J Hematol. 2015 Mar;90(3):225-9. doi: 10.1002/ajh.23916. Epub 2015 Jan 16. Am J Hematol. 2015. PMID: 25488524 Free article.

187

Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

Hasselbalch HC, Bjørn ME. Hasselbalch HC, et al. N Engl J Med. 2015 Apr 23;372(17):1670. doi: 10.1056/NEJMc1502524. N Engl J Med. 2015. PMID: 25901433 No abstract available.

188

A new internet-based tool for reporting and analysing patient-reported outcomes and the feasibility of repeated data collection from patients with myeloproliferative neoplasms.

Brochmann N, Zwisler AD, Kjerholt M, Flachs EM, Hasselbalch HC, Andersen CL. Brochmann N, et al. Among authors: hasselbalch hc. Qual Life Res. 2016 Apr;25(4):835-46. doi: 10.1007/s11136-015-1125-1. Epub 2015 Sep 11. Qual Life Res. 2016. PMID: 26358064

189

Is thrombocytosis a valid indicator of advanced stage and high mortality of gynecological cancer?

Andersen CL, Eskelund CW, Siersma VD, Felding P, Lind B, Palmblad J, Bjerrum OW, Friis S, Hasselbalch HC, de Fine Olivarius N. Andersen CL, et al. Among authors: hasselbalch hc. Gynecol Oncol. 2015 Nov;139(2):312-8. doi: 10.1016/j.ygyno.2015.09.017. Epub 2015 Sep 25. Gynecol Oncol. 2015. PMID: 26407478 No abstract available.

190

Prevalence and clinical significance of neutropenia discovered in routine complete blood cell counts: a longitudinal study.

Andersen CL, Tesfa D, Siersma VD, Sandholdt H, Hasselbalch H, Bjerrum OW, Felding P, Lind B, Olivarius Nde F, Palmblad J. Andersen CL, et al. J Intern Med. 2016 Jun;279(6):566-75. doi: 10.1111/joim.12467. Epub 2016 Jan 21. J Intern Med. 2016. PMID: 26791682 Free article.

191

The Danish National Chronic Myeloid Neoplasia Registry.

Bak M, Ibfelt EH, Stauffer Larsen T, Rønnov-Jessen D, Pallisgaard N, Madelung A, Udby L, Hasselbalch HC, Bjerrum OW, Andersen CL. Bak M, et al. Among authors: hasselbalch hc. Clin Epidemiol. 2016 Oct 25;8:567-572. doi: 10.2147/CLEP.S99462. eCollection 2016. Clin Epidemiol. 2016. PMID: 27822101 Free PMC article. Review.

192

A nationwide population-based cross-sectional survey of health-related quality of life in patients with myeloproliferative neoplasms in Denmark (MPNhealthSurvey): survey design and characteristics of respondents and nonrespondents.

Brochmann N, Flachs EM, Christensen AI, Andersen CL, Juel K, Hasselbalch HC, Zwisler AD. Brochmann N, et al. Among authors: hasselbalch hc. Clin Epidemiol. 2017 Mar 2;9:141-150. doi: 10.2147/CLEP.S117587. eCollection 2017. Clin Epidemiol. 2017. PMID: 28280390 Free PMC article.

193

Anemia is present years before myelodysplastic syndrome diagnosis: Results from the pre-diagnostic period.

Hansen JW, Sandholdt H, Siersma V, Ørskov AD, Holmberg S, Bjerrum OW, Hasselbalch HC, Olivarius NF, Grønbaek K, Andersen CL. Hansen JW, et al. Among authors: hasselbalch hc. Am J Hematol. 2017 Jul;92(7):E130-E132. doi: 10.1002/ajh.24757. Epub 2017 May 26. Am J Hematol. 2017. PMID: 28383148 Free article. Clinical Trial. No abstract available.

194

Myeloproliferative Neoplasms in Danish Twins.

Andersen MA, Bjerrum OW, Ranjan A, Skov V, Kruse TA, Thomassen M, Skytthe A, Hasselbalch HC, Christensen K. Andersen MA, et al. Among authors: hasselbalch hc. Acta Haematol. 2018;139(3):195-198. doi: 10.1159/000488384. Epub 2018 May 2. Acta Haematol. 2018. PMID: 29719285

195

Publisher Correction: Epigenetic changes in myelofibrosis: Distinct methylation changes in the myeloid compartments and in cases with ASXL1 mutations.

Nielsen HM, Andersen CL, Westman M, Kristensen LS, Asmar F, Kruse TA, Thomassen M, Larsen TS, Skov V, Hansen LL, Bjerrum OW, Hasselbalch HC, Punj V, Grønbæk K. Nielsen HM, et al. Among authors: hasselbalch hc. Sci Rep. 2018 Nov 20;8(1):17311. doi: 10.1038/s41598-018-35596-w. Sci Rep. 2018. PMID: 30459458 Free PMC article.

196

Anxiety and depression in patients with Philadelphia-negative myeloproliferative neoplasms: a nationwide population-based survey in Denmark.

Brochmann N, Flachs EM, Christensen AI, Bak M, Andersen CL, Juel K, Hasselbalch HC, Zwisler AD, Rottmann N. Brochmann N, et al. Among authors: hasselbalch hc. Clin Epidemiol. 2018 Dec 18;11:23-33. doi: 10.2147/CLEP.S162688. eCollection 2019. Clin Epidemiol. 2018. PMID: 30588121 Free PMC article.

197

Smoking and Increased White and Red Blood Cells.

Pedersen KM, Çolak Y, Ellervik C, Hasselbalch HC, Bojesen SE, Nordestgaard BG. Pedersen KM, et al. Among authors: hasselbalch hc. Arterioscler Thromb Vasc Biol. 2019 May;39(5):965-977. doi: 10.1161/ATVBAHA.118.312338. Arterioscler Thromb Vasc Biol. 2019. PMID: 30866659 Free article.

198

Variant-specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay.

Kjaer L, Skov V, Andersen MT, Aggerholm A, Clair P, Gniot M, Soeby K, Udby L, Dorff MH, Hasselbalch H, Pallisgaard N. Kjaer L, et al. Eur J Haematol. 2019 Jul;103(1):26-34. doi: 10.1111/ejh.13238. Epub 2019 May 1. Eur J Haematol. 2019. PMID: 30985947

199

Association of the blood eosinophil count with end-organ symptoms.

Bjerrum OW, Siersma V, Hasselbalch HC, Lind B, Andersen CL. Bjerrum OW, et al. Among authors: hasselbalch hc. Ann Med Surg (Lond). 2019 Jul 9;45:11-18. doi: 10.1016/j.amsu.2019.06.015. eCollection 2019 Sep. Ann Med Surg (Lond). 2019. PMID: 31360453 Free PMC article.

200

Smoking, blood cells and myeloproliferative neoplasms: meta-analysis and Mendelian randomization of 2·3 million people.

Jayasuriya NA, Kjaergaard AD, Pedersen KM, Sørensen AL, Bak M, Larsen MK, Nordestgaard BG, Bojesen SE, Çolak Y, Skov V, Kjaer L, Tolstrup JS, Hasselbalch HC, Ellervik C. Jayasuriya NA, et al. Among authors: hasselbalch hc. Br J Haematol. 2020 Apr;189(2):323-334. doi: 10.1111/bjh.16321. Epub 2019 Dec 25. Br J Haematol. 2020. PMID: 31875952 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

319 results

Search Page

Filters